| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/04/2002 | US20020039768 Percyquinnin, a process for its production and its use as a pharmaceutical |
| 04/04/2002 | US20020039745 Anti-inflammatory compositions and method |
| 04/04/2002 | US20020039734 Detecting preferential lymphocytes in sample; obtain lymphocyte, compare concentration of markers with wild type, adjustment in concentration of markers indicates presence of helper lymphocytes |
| 04/04/2002 | US20020039726 Aids viricides |
| 04/04/2002 | US20020039599 Calibration; administering antiseptic compound |
| 04/04/2002 | US20020039598 Stabilized pharmaceutical composition and its production |
| 04/04/2002 | US20020039597 Stabilized compositions containing benzimidazole-type compounds |
| 04/04/2002 | US20020039595 Capsule dosage units |
| 04/04/2002 | US20020039579 Immunoglobulin antibodies |
| 04/04/2002 | US20020039569 Activation; separation |
| 04/04/2002 | US20020039567 Wound healing agent; genetic engineering |
| 04/04/2002 | US20020039561 Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents |
| 04/04/2002 | DE10046838A1 Verwendung von Myxoxanthophyll und/oder Echinenon zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten, durch oxidative Prozesse bedingten oder begünstigten körperlichen Zuständen Use of Myxoxanthophyll and / or echinenone for prophylactic and / or therapeutic treatment of unwanted situations due to oxidative processes beneficiary physical conditions |
| 04/04/2002 | DE10045845A1 Xenon als Arzneimittel Xenon as medicinal |
| 04/04/2002 | DE10045831A1 Anticonvulsant, anxiolytic and especially analgesic medicaments, comprising new or known beta-thio-alpha-aminoacid compounds having strong affinity for gabapentin binding site |
| 04/04/2002 | DE10045829A1 Volatile Anästhesiemittel mit Xenon Volatile anesthetic xenon |
| 04/04/2002 | DE10045380A1 Verfahren zur Kontrazeption und dessen Darreichungsform Method of contraception and its dosage form |
| 04/04/2002 | DE10044846A1 Mittel mit verlängerter Magenverweilzeit zur Erzeugung eines langanhaltenden Sättigungseffektes sowie dessen Verwendung Agent with a prolonged gastric residence to produce a long-lasting satiation effect and its use |
| 04/04/2002 | DE10044831A1 Verbessertes Verfahren zur mikrobiellen Herstellung von L-Serin sowie ein dazu geeigneter genetisch veränderter Mikroorganismus An improved method for the microbial production of L-serine as well as a thereto suitable genetically modified microorganism |
| 04/04/2002 | DE10044805A1 Regulation of the function of uncoupling proteins, e.g. in treatment of obesity, diabetes and neurodegenerative diseases, comprises use of coenzyme Q or analogues as a cofactor |
| 04/04/2002 | DE10044792A1 Substituierte Phenylcyclohexancarbonsäureamide und ihre Verwendung Substituted Phenylcyclohexancarbonsäureamide and their use |
| 04/04/2002 | DE10044353A1 Unkompetitive Inhibitoren der Helikase-Primase Uncompetitive inhibitors of the helicase-primase |
| 04/04/2002 | DE10044327A1 Verwendung von Ectoin oder Ectoin-Derivaten zur Mundpflege Use of ectoine or ectoine derivatives for oral care |
| 04/04/2002 | DE10043975A1 Aqueous solution for foot care, especially for use as foot bath, containing water and plant extract(s), also contains sodium chloride, carboxylic acid(s) and iodine |
| 04/04/2002 | DE10043846A1 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen 17-methyl steroids, processes for their preparation and pharmaceutical compositions containing this compound |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2426117A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| 04/04/2002 | CA2425749A1 Otic microbial combinations for treatment of animals with ruptured tympanic membrane |
| 04/04/2002 | CA2424949A1 Pharmaceutical oxan preparation |
| 04/04/2002 | CA2424038A1 Coated medical devices |
| 04/04/2002 | CA2424021A1 Catecholamine compositions and uses thereof |
| 04/04/2002 | CA2424013A1 Triterpenes having fungicidal activity against yeast |
| 04/04/2002 | CA2423978A1 Potassium salt of thiazolidinedione and its use as antidiabetic |
| 04/04/2002 | CA2423975A1 Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 04/04/2002 | CA2423919A1 Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai |
| 04/04/2002 | CA2423903A1 O-substituted 6-methyltramadol derivatives |
| 04/04/2002 | CA2423746A1 Method of achieving overnight laxation and control of bowel function |
| 04/04/2002 | CA2423694A1 Transferases |
| 04/04/2002 | CA2423585A1 Analgesic and glucosamine compositions |
| 04/04/2002 | CA2423487A1 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 04/04/2002 | CA2423482A1 Fluorinated quinolones as antimitotic and antitumor agents |
| 04/04/2002 | CA2423474A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | CA2423464A1 Hydroxy acid integrin antagonists |
| 04/04/2002 | CA2423449A1 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 04/04/2002 | CA2423434A1 Lactone integrin antagonists |
| 04/04/2002 | CA2423413A1 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 04/04/2002 | CA2423313A1 Methods of treating inflammatory and immune reactions and compositions therefor |
| 04/04/2002 | CA2423305A1 Compounds useful in the treatment of inflammatory diseases |
| 04/04/2002 | CA2423251A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | CA2423201A1 Stabilized hydrogen peroxide solutions |
| 04/04/2002 | CA2423141A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 04/04/2002 | CA2422916A1 Compounds and methods for use thereof in the treatment of cancer or viral infections |
| 04/04/2002 | CA2422873A1 Piperazin-2-one amides as inhibitors of factor xa |
| 04/04/2002 | CA2422530A1 Human drug metabolizing enzymes |
| 04/04/2002 | CA2422056A1 17.alpha. fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds |
| 04/04/2002 | CA2421729A1 Fatty acid analogues for the treatment of proliferative skin disorders |
| 04/04/2002 | CA2421620A1 Promoter sequences |
| 04/04/2002 | CA2421209A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases |
| 04/04/2002 | CA2420851A1 .alpha.-substituted .beta.-aminoethyl phosphonates |
| 04/04/2002 | CA2418260A1 Erythromycin derivative and medicament comprising the same |
| 04/03/2002 | EP1193270A2 Pyrrolobenzodiazepines |
| 04/03/2002 | EP1193269A1 Crystalline 1-methylcarbapenem compounds |
| 04/03/2002 | EP1193268A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
| 04/03/2002 | EP1193267A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases |
| 04/03/2002 | EP1193266A1 Quinolinecarboxylic acid derivative or salts thereof |
| 04/03/2002 | EP1193265A2 A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides |
| 04/03/2002 | EP1193261A1 New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/03/2002 | EP1193260A1 Phenoxazine analogs for the treatment of amyloidosis |
| 04/03/2002 | EP1193257A2 Compounds for ceramide-mediated signal transduction |
| 04/03/2002 | EP1193256A1 Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins |
| 04/03/2002 | EP1193250A1 Phenyl sulfamate derivatives |
| 04/03/2002 | EP1193249A1 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 04/03/2002 | EP1193248A1 Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
| 04/03/2002 | EP1192957A2 Coating for medical devices |
| 04/03/2002 | EP1192952A2 Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| 04/03/2002 | EP1192951A2 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound |
| 04/03/2002 | EP1192950A1 Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
| 04/03/2002 | EP1192949A1 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| 04/03/2002 | EP1192947A1 Pharmaceutical composition comprising trehalose for ophthalmic use |
| 04/03/2002 | EP1192946A1 Use of mometasone furoate for treating airway passage and lung diseases |
| 04/03/2002 | EP1192945A2 Use of an estrogen agonist/antagonist for treating osteoarthritis |
| 04/03/2002 | EP1192944A1 Use of pregabalin for treating asthma |
| 04/03/2002 | EP1192943A2 Use of growth hormone secretagogues in conjunction with physical exercise |
| 04/03/2002 | EP1192940A1 Compositions and methods for promoting clear skin using an alkanolamine |
| 04/03/2002 | EP1192939A2 Methods for reduction of inflammation and erythema |
| 04/03/2002 | EP1192938A2 Composition to enhance permeation of topical skin agents |
| 04/03/2002 | EP1192450A1 High energy phototherapeutic agents |
| 04/03/2002 | EP1192275A2 Prediction of risk of interstitial lung disease |
| 04/03/2002 | EP1192271A1 Antisense modulation of interleukin-5 signal transduction |
| 04/03/2002 | EP1192266A2 Complement-resistant non-mammalian dna viruses and uses thereof |
| 04/03/2002 | EP1192248A1 Antisense modulation of ship-2 expression |
| 04/03/2002 | EP1192247A1 Sphingosine kinase enzyme |
| 04/03/2002 | EP1192187A1 Heparin compositions that inhibit clot associated coagulation factors |
| 04/03/2002 | EP1192184A1 Surfactant protein c esters |
| 04/03/2002 | EP1192174A2 Antagonists of bmp and tgf beta signalling pathways |
| 04/03/2002 | EP1192170A1 Propargyl phenyl ether a2a receptor agonists |
| 04/03/2002 | EP1192169A2 C-pyrazole a2a receptor agonists |
| 04/03/2002 | EP1192165A2 Substituted heterocycle fused gamma-carbolines |
| 04/03/2002 | EP1192164A1 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists |
| 04/03/2002 | EP1192163A1 DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |